LabGenius has raised £35 million in a Series B funding round to further develop its AI-powered antibody discovery platform. The investment, led by M Ventures, aims to enhance the company’s innovative technologies in biotherapeutics.
LabGenius is set to utilise the fresh funds to expand its machine learning capabilities specifically through its platform, EVA. By leveraging robotic automation and AI, LabGenius is poised to transform how unique biotherapeutics, such as antibodies, are identified. This strategic investment will also open doors for partnership opportunities across various therapeutic domains.
A major area of focus for LabGenius is the development of multispecific antibodies aimed at targeting solid tumours. These antibodies are crafted to precisely identify specific markers on cancer cells, thus presenting a promising frontier in oncology.
A significant hurdle in antibody innovation is the occurrence of on-target, off-tumour toxicity, where therapeutic antibodies may inadvertently bind to healthy cells. LabGenius is addressing this through its platform, optimising for both selectivity and efficacy.
Traditional antibody optimisation is often linear, targeting one property at a time.
LabGenius employs Multi-Objective Bayesian Optimisation, an approach that allows simultaneous enhancement across multiple antibody properties, thereby reducing bias and enhancing performance.
This innovative method empowers the AI to uncover highly effective antibody structures that conventional techniques might miss.
Prominent investors including M Ventures and Octopus Ventures are backing LabGenius due to its cutting-edge technology. Dr. Oliver Hardick from M Ventures highlighted the transformative potential of LabGenius’ platform.
Dr. James Field, the CEO, underscored the immense promise of multispecific antibodies and expressed his gratitude towards the team and investors for supporting their vision.
The successful funding round attests to LabGenius’ leading position in AI-driven drug discovery. Through its novel approach to overcoming challenges in antibody development, the company is setting the stage for major advancements in cancer therapy.
This progress highlights not only the potential of their technology but also the growing significance of AI in the pharmaceutical industry.
The company plans to advance its wholly-owned antibody pipeline and aims to introduce these innovations into clinical trials soon.
LabGenius remains committed to fulfilling unmet medical needs through continuous refinement and development of its AI-powered platform.
LabGenius exemplifies the transformative power of AI in reshaping biopharmaceutical research, presenting a model for future developments.
LabGenius’ £35 million Series B funding underscores its pioneering role in the AI-driven biotherapeutics landscape. With continued advancements, the company is well-positioned to revolutionise antibody discovery, promising improved cancer treatments.
